The global Postmenopausal Osteoporosis Market is estimated to be valued at US$ 4747.9 Mn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Postmenopausal osteoporosis refers to low bone mineral density and fragile bones that occurs in women after menopause. Postmenopausal osteoporosis increases the risk of bone fractures. Drugs to treat postmenopausal osteoporosis works by inhibiting bone resorption and promoting new bone formation. These drugs help increase bone mineral density and reduce the risk of fractures. The need for drugs to effectively treat postmenopausal osteoporosis and reduce complications is increasing.
Market key trends:
One of the key trends in the postmenopausal osteoporosis market is the increasing research and development for novel anabolic drugs. Currently approved drugs for postmenopausal osteoporosis mainly reduce bone resorption but have little effect on bone formation. Researchers are exploring new molecules that can directly stimulate bone formation like parathyroid hormone analogs. These novel anabolic drugs are expected to more effectively treat postmenopausal osteoporosis and reduce fracture risk compared to existing anti-resorptive drugs.
Threat of new entrants: The threat of new entrants is low in this market as it requires substantial R&D investment and clinical trials to develop drugs for postmenopausal osteoporosis. Established manufacturers have significant production capacity and brand recognition.
Bargaining power of buyers: The bargaining power of buyers is moderate as the treatment landscape includes both branded and generic drugs. Buyers can negotiate on price and switch between therapeutic alternatives.
Bargaining power of suppliers: Suppliers of active pharmaceutical ingredients (APIs) and contract manufacturing organizations have moderate bargaining power due to the availability of substitutes and less fluctuation in production costs.
Threat of new substitutes: The threat of new substitutes is high due to ongoing research on newer treatment mechanisms and drug formulations. Biosimilars also act as substitutes when patents expire on originator biologics.
Competitive rivalry: Intense due to the presence of many global and regional manufacturers.
The Global Postmenopausal Osteoporosis Market Size is expected to witness high growth, exhibiting CAGR of 4.4% over the forecast period, due to increasing geriatric population prone to osteoporosis and subsequent fractures.
The North American region currently dominates the postmenopausal osteoporosis market owing to the increasing awareness regarding osteoporosis and rising healthcare expenditure in the region. However, the Asia Pacific region is expected to exhibit the highest growth rate over the forecast period due to the growing seniors population and improving healthcare infrastructure in emerging countries of China and India.
Key players operating in the postmenopausal osteoporosis market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it